A study of effect of guggulsterone on hyperlipidemia of secondary glomerulopathy

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Secondary glomerulopathies often present with hyperlipidemia, a condition linked to increased risks of atherosclerosis, coronary artery disease, hypertension, cerebrovascular accidents, and thromboembolic events.
• Effective management of hyperlipidemia in these patients is crucial for altering prognosis and preventing severe complications, including renal failure.

Purpose of the Study:

• To investigate the efficacy of Guggulsterone in managing hyperlipidemia within patients diagnosed with secondary glomerulopathies.
• To assess the impact of Guggulsterone on various lipid profile parameters and its overall safety profile over an 8-week treatment period.

Main Methods:

• A cohort of patients with secondary glomerulopathies received oral Guggulsterone (75 mg daily in divided doses) for 8 weeks.
• Supportive therapies including high-protein diet, diuretics, and hematinics were administered concurrently.
• Lipid profiles, including total serum lipid, total serum cholesterol, triglycerides, phospholipids, HDL, LDL, and VLDL, were analyzed at baseline, 4 weeks, and 8 weeks.

Main Results:

• A statistically significant reduction was observed in total serum lipid and total serum cholesterol levels after 8 weeks of Guggulsterone therapy.
• Other lipid parameters, such as triglycerides, phospholipids, LDL, and VLDL, showed a downward trend, although not always statistically significant.
• High-density lipoprotein (HDL) levels exhibited an upward trend, but the difference was not statistically significant. No significant adverse effects were reported during the study.

Conclusions:

• Guggulsterone demonstrates significant efficacy in reducing total serum lipids and cholesterol in patients with secondary glomerulopathies.
• The compound appears to be well-tolerated, with no significant side effects observed, suggesting its potential as a therapeutic agent for managing dyslipidemia in this patient population.
• Further research is warranted to explore the long-term effects and optimal use of Guggulsterone in secondary glomerulopathies to mitigate associated cardiovascular and renal risks.